Isolation of non-hematopoietic stem cells from umbilical cord blood  by Wernet, P. et al.
180 revealed no differences except a signiﬁcantly greater risk of
viral infections in TCD recipients from day 0-42 (TCD vs BM RR
3.5, p  0.02). After day 180, TCD recipients had the greatest
infection risk, whereas UCB recipients had the lowest risk TCD vs
BM RR 3.1, p 0.03; UCB vs BM RR 0.5, p 0.23). Multivariate
Cox regression analysis revealed that age 8 years, TCD, and
severe acute GVHD were each associated with increased infection
risk. These data suggest that the immune reconstitution after UCB
transplantation is superior to that seen with TCD, and is as good
as with unmanipulated BM.
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TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Shpall, E.J.1, McNiece, I.K.2, de Lima, M.1, McMannis, J.D.1, Robin-
son, S.1, Peled, T.3, Champlin, R.E.1, 1. The M.D. Anderson Bone
Marrow Transplant Department, Houston, TX; 2. Johns Hopkins On-
cology Center, Baltimore, MD; Gamida Cell Ltd.
Umbilical cord blood (CB) from unrelated donors is increasingly
used to restore hematopoiesis after myeloablative or more recently,
nonmyeloablative therapy. CB transplants are associated with
higher rates of delayed and failed engraftment than are bone
marrow transplants, particularly for adult patients. At the Univer-
sity of Colorado, we studied the ex vivo expansion of CB in an
attempt to improve time to engraftment and reduce the graft
failure rate in the recipients. In the study, 43 patients with hema-
tologic malignancies (n  40) or breast cancer (n  3) received
high-dose therapy followed by unrelated allogeneic CB transplan-
tation [1]. A fraction of each patient’s CB allograft was CD34-
selected and cultured ex vivo for 10 or 14 days prior to transplan-
tation in deﬁned media with stem cell factor (SCF), granulocyte
colony-stimulating factor (G-CSF), and megakaryocyte growth
and differentiation factor (MGDF). The remainder of the CB graft
was infused without further manipulation. Two sequential cohorts
of patients were accrued to the study. The ﬁrst cohort had 40% and
the second cohort had 60% of their CB graft expanded. This study
demonstrated that the CD34 selection and ex vivo expansion of CB
prior to transplantation is feasible. The engraftment failure rate
was relatively low, and the time to neutrophil in large adults was in
the range reported for pediatric recipients of much larger CB cell
doses.
In the successor cord expansion trial being conducted at the
M.D. Anderson Cancer Center, several changes in the approach
have been made. Patients with hematologic malignancies are now
being randomized to receive either two unmanipulated CB units or
one unmanipulated unit and one unit from which all the cells are
expanded ex vivo. For the patients randomized to expansion, on
day 14 one of their cord units is AC133-selected using the
CliniMACS device. The AC133-negative fraction containing the
T cells is frozen and the AC133 fraction is cultured ex vivo for 14
days in media containing SCF, G-CSF and thrombopoietin
(TPO). Following administration of the preparative regimen, on
Day 0, the second unmanipulated CB unit is infused, followed by
the thawed AC133-negative fraction and ﬁnally, the fraction which
has been in culture for two weeks. This trial was recently initiated
and accrual is in progress.
Another expansion trial technology involves the use of a copper
chelating agent, which has been shown by Peled et al to enhance
the expansion of a more primitive CD34 CB population when
combined with early acting growth factors. A clinical trial employ-
ing this technology is in progress at M.D. Anderson. Patients with
hematologic malignancies undergoing CB transplantation, with a
unit that is cryopreserved in two fractions are eligible for the study.
Twenty one days prior to infusion, the AC133 cells are isolated
from the smaller cord fraction using the CliniMACS device and
cultured for three weeks in media containing interleukin-6 TPO,
FLT-3, SCF, and the copper chelator tetraethylenepentamine
(TEPA). The patients then receive high-dose therapy with the
infusion of the larger, unmanipulated CB fraction on day 0, and
infusion of the smaller expanded fraction of day1. Thus far eight
patients have been enrolled on the study and the results will be
forthcoming.
Future directions include the use of mesenchymal stem cells as a
supportive stroma for the expansion of CB mononuclear cell pro-
genitors, developed by McNiece et al. This approach would obvi-
ate the need for CD34 or AC133-selection, as those procedures are
associated with substantial losses of CD34 CB cells
1. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex
vivo expanded cord blood. Biol Blood Marrow Transplant.
2002;8:368-376.
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CGMP MANUFACTURE OF THE MULTIPOTENT ADULT PROGENITOR
CELL (MAPC) AND STRATEGY FOR CLINICAL TESTING
Wagner, J.E., Verfaillie, C.M. Blood and Marrow Transplant Program
and Stem Cell Institute, University of Minnesota, Minneapolis, MN.
MAPC are a rare cell population found in adult bone marrow
(BM) that proliferate for extended periods without obvious senes-
cence. MAPC differentiate into mesodermal, neuroectodermal and
endodermal tissues. Further, MAPC contribute to most somatic
tissues when injected into an early blastocyst, and can engraft in
post-natal animals where they can differentiate into tissue-speciﬁc
cell types. Therefore, we hypothesize that MAPC may be useful in
the treatment of a variety of degenerative and inherited diseases
and traumatic injury. Prior to clinical testing, however, MAPC
must be produced in accordance with cGMP. This will require: 1)
production of clinical grade reagents (i.e., sterile, endotoxin and
mycoplasma free), 2) optimization of process components to min-
imize surface areas required for cell expansion, 3) deﬁnition of a
closed cell expansion system integrated with blood cell processing
procedures and equipment, 4) process validation and establishment
of quality assurance documentation, and validation of the assays
themselves used for quality control (QC) and product release.
After clinical manufacture, MAPC lot release criteria will include
a demonstration of: 1) purity as measured by cell surface antigen
expression (MAPC are CD45neg, MHCneg, CD13) and quan-
titative RT-PCR for the transcription factor oct4; 2) proliferative
capacity as measured ability to be promulgated in culture for 70
doublings without telomere shortening and without cytogenetic
abnormalities, and 3) pluripotency, as demonstrated by ability to
differentiate into tissue-speciﬁc cells of each lineage. In parallel to
efforts to develop a large scale clinical manufacture procedure,
there has been considerable effort to the selection of a clinical
model for the testing of MAPC. As it is hypothesized that MAPC
will distribute and proliferate in tissues of various organs, partic-
ularly in response to tissue injury, the ﬁrst clinical trial will be in
recipients of high dose chemoradiotherapy in whom high regimen
related toxicity (i.e., as evidenced by injury to the gastrointestinal
tract, liver and lung) severely limits survival.
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ISOLATION OF NON-HEMATOPOIETIC STEM CELLS FROM UMBILICAL
CORD BLOOD
Wernet, P., Fischer, J., Caplan, A., Zanjani, E., Müller, H.W., Knip-
per, A., Kögler, G.
An intrinsically pluripotent, CD45 negative population from
placental cord blood, termed unrestricted somatic stem cells
(USSC) as a rare population grows adherently and can be expanded
to large quantities of cells without losing pluripotency. Thus, in
vitro USSC homogeneous differentiation into osteoblasts, chon-
droblasts, adipocytes, hematopoietic and neural cells including
astrocytes and neurons expressing neuroﬁlament, sodium channel
protein and various neurotransmitter phenotypes are demon-
strated. Stereotactic implantation of USSC into intact adult rat
brain revealed that human Tau-positive cells persisted for several
months, showing migratory activity and a typical neuron-like mor-
phology. In vivo differentiation of USSC along mesodermal and
endodermal pathways was demonstrated in animal models. Bony
reconstitution was observed after transplantation of USSC-loaded
calcium phosphate cylinders in nude rat femurs. Chondrogenesis
occurred after transplanting cell-loaded Gelfoam sponges into
nude mice. Transplantation of USSC in a non-injury model, the
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preimmune fetal sheep, resulted in up to 5% human hematopoietic
engraftment. More than 20% albumin-producing human paren-
chymal hepatic cells with absence of cell fusion as well as substan-
tial numbers of human cardiomyocytes in both atria and ventricles
of the sheep heart were detected still over one year following
USSC transplantation. No malignant cell transformation was ob-
served in any of these animals.
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CORD BLOOD CRYOBIOLOGY: IMPACT ON TRANSPLANT OUTCOMES
Creer, M.H. Department of Pathology and Pediatrics, St. Louis Uni-
versity, St. Louis Cord Blood Bank, St. Louis, MO.
The therapeutic potential of cord blood (CB) for hematopoietic
stem/progenitor cell (HSC) transplantation is primarily limited by
the number (dose) of functionally viable HSC administered to the
transplant recipient. The process of cryopreservation and thawing
of CB products is the single greatest and most variable source of
HSC loss from collection to infusion and the effects of cryopreser-
vation and thaw on CB HSC function are inherent in all published
comparisons of CB versus BM or PBSC transplant outcome. We
performed a series of studies to examine the effects of cooling rate
(CR) and type of cryoprotectant (DMSO, propanediol) on CB
HSC cell number (TNC and CD34), viability (trypan blue,
7-AAD) and function (CFU assay) post-thaw. Varying the CR
from 1 to 20 deg. C/min. had little effect on recovery (%) of
CB HSC number and trypan blue viability (%), however, CB HSC
function (CFU recovery (%)) decreased markedly at CR above 5
deg. C/min. Monitoring of the CR of cord blood units is subject to
artifacts arising from alterations in thermistor probe placement
necessitating careful review of cooling curves and on-site validation
of the cryopreservation system. Frozen CB units placed in liquid
N2 must occasionally be transferred to other locations or tempo-
rarily removed from liquid N2 for retrieval of attached segments
exposing the unit to potential warming effects (PWE). Transfer of
CB units in Styrofoam containers with liquid N2 or segment
removal in liquid N2 vapor does not cause any detectable loss of
HSC number, viability or function. Similarly, repeated exposure of
frozen CB units to 10 consecutive 1 min. intervals at room tem-
perature also had no signiﬁcant effect on HSC number, viability or
function. We conclude that transient warming during CB unit
transfer or segment removal does not result in measurable PWE.
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Implementation of the FDA Regulatory Approach to Cells and Tis-
sue: Focus on Cord Blood
Lazarus, E. Division of Human Tissues, Ofﬁce of Cellular, Tissue, and
Gene Therapies, Center for Biologics Evaluation and Research, FDA.
How is cord blood regulated?
In response to the initiative to “reinvent” the regulation of
human tissue, the FDA published the Proposed Approach to Reg-
ulation of Cellular and Tissue-Based Products (Federal Register
2/28/1997). To implement this approach, three new rules are to be
codiﬁed in 21 CFR 1271:
Establishment Registration and Listing
Donor Eligibility
Current Good Tissue Practices (cGTP)
All manufacturers of human cells, tissue, and cell and tissue-based
products (HCT/P), including cord blood, will be required to com-
ply with these regulations when ﬁnalized. HCT/Ps that have a
metabolic function such as cord blood require additional controls;
these products are also regulated as biologics under the authority of
section 351 of the Public Health Service Act.
Cell or tissue products requiring FDA premarket approval meet
any of the following criteria:
● Expanded, activated, genetically modiﬁed or otherwise more
than minimally manipulated
● Combined with a drug or device, with some exceptions
● Labeled or advertised for non-homologous use, such as HPC
delivered for cardiac repair
● Clinical effect is systemic or dependent upon the metabolic
activity of the cells, except if for autologous use, or use in a ﬁrst or
second-degree blood relative. Example: allogeneic, unrelated do-
nor cord and peripheral blood stem/progenitor cells
Phase-in of FDA approval requirements for some hemato-
poletic progenitor cell products (HPC)
Allogeneic unrelated minimally manipulated HPC for hemato-
poietic reconstitution require assurance of clinical safety and ef-
fectiveness. Cord blood and peripheral blood stem/progenitor cell
products from unrelated donors are subject to “phase-in” of IND
and licensure requirements. As described in the Federal Register
notice entitled “Request for Proposed Standards for Unrelated
Allogeneic Peripheral and Placental/Umbilical Cord Blood Hema-
topoietic Stem/Progenitor Cell Products; Request for Comments”
published 1/20/1998, standaros may be developed for these HPC
products if data exist to show safety and effectiveness when man-
ufactured in accordance with certain deﬁned product speciﬁcations
and process controls.
Finalization and Implementation of 21 CFR Part 1271: cur-
rent status
Finalizing the three rules that together will be codiﬁed as 21 CFR
Part 1271 is a current FDA priority. The establishment registra-
tion and listing ﬁnal rule was published in January 2001. The
establishment registration and listing interim ﬁnal rule, published
in January 2004, explains that all HCT/P establishments are now
required to register and list as of March 29, 2004, with the excep-
tion of those manufacturing human heart valves and dura mater.
This interim rule will be revoked when all of Part 1271 becomes
effective.
The ﬁnal donor eligibility rule was published on May 25, 2004,
and becomes effective on May 25, 2005. It is accompanied by draft
guidance that provides recommendations for complying with the
requirements in the donor eligibility rule. Comments on the draft
guidance should be received by August 23, 2004 (90 days from the
publication date) to ensure consideration in the ﬁnal guidance. The
rule is available on FDA’s website at www.fda.gov/OHRMS/
DOCKETS/98fr/97N-484S-nfr0001.pdf and the guidance is
available at www.fda.gov/cber/gdlns/tissdonor.pdf. Publication of
the ﬁnal GTP rule is expected soon. The changes to the ﬁnal rules
address many of the concerns raised by cell therapy and blood bank
professional associations and establishments, submitted as com-
ments to the docket.
Possible issues for international exchange with the U.S.
Non-U.S. manufacturers are required to annually register with
FDA if their HPC products are used in the U.S. These manufac-
turers must complete the form 3356 and indicate a U.S. Agent. All
donor testing must be performed in CLIA accredited laboratories
using FDA cleared/approved test kits. Currently there are more
than 40 registered HPC facilities outside of the U.S.
Summary
Implementation of the regulatory approach to human cell and
tissue products is nearing completion. The period of enforcement
discretion for unrelated donor cord blood is ongoing, pending
determination of whether there are adequate data to support a
standards-based approach to licensure. Cord blood manufacturers
currently must register with the FDA, and will be required to
comply with DE and GTP requirements when ﬁnalized and effec-
tive.
Information Available
The website at www.fda.gov/cber/tiss.htm has links to the down-
loadable Form 3356 (Registration/listing), all published documents
and letters; and relevant meeting minutes, summaries, transcripts,
and presentations. The e-mail address for registration questions is
tissuereg@cber.fda.gov.
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